Eidos Therapeutics
Palo Alto
About Eidos Therapeutics
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $64.0M
- Funding stage: M&A
- Last round: Series B (Apr 2018)
- Ticker: nasdaq:EIDX
- Website: eidostx.com
- Phone: 650-656-9920
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/eidos-therapeutics-111750 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.